Will the Label Expansion of Trodelvy Strengthen GILD's Oncology Portfolio?Zacks Investment Research • 07/06/26
Gilead Sciences (GILD) Dips More Than Broader Market: What You Should KnowZacks Investment Research • 06/25/26
Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded UseZacks Investment Research • 06/25/26
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast CancerBusiness Wire • 06/24/26
For decades, the only first treatment for one of the deadliest breast cancers was standard chemotherapy. Now there are two newly approved drugs.WSJ • 06/24/26
Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBCZacks Investment Research • 06/24/26
European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 InhibitorsBusiness Wire • 06/23/26
FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV PreventionZacks Investment Research • 06/16/26
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to KnowZacks Investment Research • 06/15/26
U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV PreventionBusiness Wire • 06/15/26
The Hormuz Reopening Trade: These 20 Large-Cap Stocks Still Haven't Caught Up To Pre-War LevelsBenzinga • 06/15/26
Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak ReliefBusiness Wire • 06/12/26
Pharma and Biotech M&A Boom Accelerates as Companies Expand PipelinesZacks Investment Research • 06/11/26
National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community LeadershipBusiness Wire • 06/11/26
Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/10/26
Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC StudyZacks Investment Research • 06/09/26
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV TreatmentBusiness Wire • 06/08/26